Single-domain antibodies for biomedical applications |
| |
Authors: | Simon Krah Christian Schröter Stefan Zielonka Martin Empting Bernhard Valldorf |
| |
Affiliation: | 1. Protein Engineering and Antibody Technologies, Merck-Serono, Merck KGaA, Darmstadt, Germany,;2. Institute for Organic Chemistry and Biochemistry, Technische Universit?t Darmstadt, Darmstadt, Germany, and;3. Department Drug Design and Optimization, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrücken, Germany |
| |
Abstract: | AbstractSingle-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or constant antibody domains of the heavy or light chain. Because of their high affinity and specificity as well as stability, small size and benefit of multiple re-formatting opportunities, those molecules emerged as promising candidates for biomedical applications and some of these entities have already proven to be successful in clinical development. |
| |
Keywords: | Antibody engineering antibody fragment heavy chain antibody single chain binding domain IgNAR VHH |
|
|